



Corrigendum: Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study

Narmeen Mallah^{1,2}, Maruxa Zapata-Cachafeiro^{1,2*}, Carmelo Aguirre^{3,4,5}, Eguzkiñe Ibarra-García^{3,6}, Itziar Palacios-Zabalza^{3,4}, Fernando Macías-García⁷, J. Enrique Domínguez-Muñoz⁷, María Piñeiro-Lamas^{2,8}, Luisa Ibáñez⁹, Xavier Vidal⁹, Lourdes Vendrell⁹, Luis Martín-Arias¹⁰, María Sáinz-Gil¹⁰, Verónica Velasco-González¹⁰ and Adolfo Figueiras^{1,2,8} on behalf of the EMPHOGEN group

OPEN ACCESS

Edited and reviewed by:

José A. G. Agúndez,
University of Extremadura, Spain

*Correspondence:

Maruxa Zapata-Cachafeiro
maruxa.zapata@usc.es

Specialty section:

This article was submitted to
Pharmacogenetics and
Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology

Received: 13 June 2020

Accepted: 01 July 2020

Published: 17 July 2020

Citation:

Mallah N, Zapata-Cachafeiro M, Aguirre C, Ibarra-García E, Palacios-Zabalza I, Macías-García F, Domínguez-Muñoz JE, Piñeiro-Lamas M, Ibáñez L, Vidal X, Vendrell L, Martín-Arias L, Sáinz-Gil M, Velasco-González V, and Figueiras A (2020) Corrigendum: Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study. *Front. Pharmacol.* 11:1072. doi: 10.3389/fphar.2020.01072

¹ Department of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain, ² Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Carlos III Health Institute, Madrid, Spain, ³ Biocruces Bizkaia Health Research Institute, Pharmacotherapy Group, Bizkaia, Spain, ⁴ University Hospital of Galdakao-Usansolo, Basque Country Pharmacovigilance Unit, Osakidetza, Spain, ⁵ Pharmacology Department, Medicine and Nursing Faculty, University of the Basque Country, Barakaldo, Bizkaia, Spain, ⁶ Osakidetza Basque Health Service, Urduliz Hospital, Pharmacy Department, Urduliz, Spain, ⁷ Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain, ⁸ Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, ⁹ Department of Pharmacology, Therapeutics and Toxicology, Catalan Institute of Pharmacology, Clinical Pharmacology Service, Vall d'Hebron University Teaching Hospital, Autonomous University, Barcelona, Spain, ¹⁰ Centre for Research on Drug Safety (CESME), Valladolid University, Valladolid, Spain

Keywords: aspirin, upper gastrointestinal haemorrhage, genetic polymorphism, pharmacogenomics, platelet, interaction

A Corrigendum on

Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study

by Mallah N, Zapata-Cachafeiro M, Aguirre C, Ibarra-García E, Palacios-Zabalza I, Macías-García F, Domínguez-Muñoz JE, Piñeiro-Lamas M, Ibáñez L, Vidal X, Vendrell L, Martín-Arias L, Sáinz-Gil M, Velasco-González V and Figueiras A (2020) Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study. *Front. Pharmacol.* 11:860. doi: 10.3389/fphar.2020.00860

In the original article, there was an error. The title lacks the first two words “Influence of.” A correction has been made to the title: *Influence of Polymorphisms Involved in Platelet Activation and Inflammatory Response on Aspirin-Related Upper Gastrointestinal Bleeding: A Case-Control Study.*

Furthermore, the name of one of the authors was incorrectly spelled in the **References** section as “Throat and Cuzick, 2015.” It should be “Thorat and Cuzick, 2015.”

Finally, in the original article, there was a typing error. A correction has been made to the section **Results**, subsection **Study Population**, Paragraph 1:

“Of 5,896 interviewed subjects, 326 cases and 748 controls were eligible to be included in the final analysis. The most common exclusion criteria were ineligible endoscopic diagnosis (1,590 cases) and unavailability of biological material (328 cases and 749 controls). The flow diagram of cases and controls enrollment in the study and the reasons of exclusion are presented in supplementary data online (see **Figure S1** and **Table S1** of the supplementary materials attached to this

article). **Table 1** summarizes the demographic and clinical characteristics of the study population.”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Mallah, Zapata-Cachafeiro, Aguirre, Ibarra-García, Palacios-Zabalza, Macías-García, Domínguez-Muñoz, Piñeiro-Lamas, Ibáñez, Vidal, Vendrell, Martín-Arias, Sáinz-Gil, Velasco-González and Figueiras. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.